Brcarib 150mg Tablet

Brcarib 150mg tablet is a first line targeted therapy which is prescribed for ovarian and breast cancer treatment In women. Its active ingredient is Olaparib and belongs to the class of PARP inhibitor. It helps by blocking the PARP enzyme as it is responsible for the growth of cancer cells in the body. It can prevent the body from further cancer cell multiplication and slow the progression of the disease. Doctor's must prescribe this medication and determine the appropriate dose and duration based on the patient's condition.

Ovarian and breast cancer

Brcarib 150mg tablet can cause side effects, some are mild and severe. The medication side effects also depend on the patient body response to the treatment. If the symptoms persist, kindly discuss with the doctor and manage the side effects effectively:
● Muscle cramps
● Confusion, visual disturbances, seizures, and headache
● Breathlessness
● Swelling of feet
● Changes in heartbeat
● High blood pressure
● Pneumonia
● Loss of appetite
● Sensitivity, tingling and burning sensation of the skin
● Nausea, vomiting, and diarrhea
● Mouth ulcers
● Constipation

Brcarib 150mg tablet should be taken orally, do not chew or crush the tablet just take it with the whole glass of water. Avoid skipping the medicine as it can affect the treatment outcomes. Consult the doctor about the correct dosage and duration of the medicine. Never adjust the dose or stop the medication on your own without medical advice.

Breast and ovarian cancer is generally caused by the mutation caused in the DNA which allow the multiplication of normal cells into cancer cells. Brcarib 150mg tablet contains PARP inhibitor which blocks the pathway of DNA mutation and slow the growth of cancer cells in the body. The medicine is used as a first line therapy in the treatment of ovarian and breast cancer. It can also be used with other combination of medications, particularly in patients with BRCA mutated or homologous recombination deficient (HRD ) tumors.

• Bochum, S., Berger, S., & Martens, U. M. (2018). Olaparib. Small molecules in oncology, 217-233.
• Deeks, E. D. (2015). Olaparib: first global approval. Drugs, 75(2), 231-240.
• Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., ... & Conte, P. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377(6), 523-533.
• de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., ... & Hussain, M. (2020). Olaparib for metastatic castration-resistant prostate cancer. New England Journal of Medicine, 382(22), 2091-2102.
• Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., ... & de Bono, J. S. (2015). DNA-repair defects and olaparib in metastatic prostate cancer. New England Journal of Medicine, 373(18), 1697-1708.